Charles River Laboratories
413 hedge funds and large institutions have $7.23B invested in Charles River Laboratories in 2019 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 146 increasing their positions, 139 reducing their positions, and 34 closing their positions.
251% more call options, than puts
Call options by funds: $38.5M | Put options by funds: $11M
85% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 34
15% more capital invested
Capital invested by funds: $6.27B → $7.23B (+$961M)
4% more funds holding
Funds holding: 396 → 413 (+17)
5% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 139
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.1% less ownership
Funds ownership: 96.97% → 96.87% (-0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$63.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.9M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$38M |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$29.2M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$46.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$32.1M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$29.6M |
| 4 |
HM
HealthCor Management
New York
|
-$26.4M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$22.6M |
CRL Hedge Fund Activity: Q4 2019 in Review
413 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2019, worth a combined $7.23B — up 15% from $6.27B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new CRL positions and 34 closed out — a net gain of 29 holders — while 146 added to existing stakes and 139 trimmed.
The largest buyer was Millennium Management, adding an estimated $63.9M. The largest seller was AQR Capital Management, cutting an estimated $46.4M.
- 413 institutional investors held Charles River Laboratories (CRL) as of Q4 2019, up from 396 in Q3 2019.
- Funds reported $7.23B of Charles River Laboratories stock for Q4 2019, up 15% quarter-over-quarter.
- 63 funds opened new Charles River Laboratories positions in Q4 2019 and 34 closed out, a net change of +29 holders.
- The largest Charles River Laboratories buyer in Q4 2019 was Millennium Management, an estimated $63.9M added.
- The largest Charles River Laboratories seller in Q4 2019 was AQR Capital Management, an estimated $46.4M sold.
Based on aggregated 13F filings for Q4 2019.